Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 10/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149166 | 0.92 | PTGS2 (0.45) | PTGS2PTGS1MTNR1AMTNR1BF10 | |
| SCHEMBL5147825 | 0.85 | PTGS2 (0.48) | PTGS2PTGS1F10 | |
| SCHEMBL5148799 | 0.84 | PTGS2 (0.49) | PTGS2PTGS1F10 | |
| SCHEMBL5148863 | 0.84 | PTGS2 (0.48) | PTGS2PTGS1F10 | |
| Hydrochloric Acid SCHEMBL5417976 | 0.83 | PTGS2 (0.48) | PTGS2PTGS1F10 | |
| SCHEMBL6687282 | 0.81 | PTGS2 (0.53) | PTGS2PTGS1MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL5150503 | 0.80 | PTGS2 (0.65) | PTGS2PTGS1 | |
| SCHEMBL5147861 | 0.80 | PTGS2 (0.65) | PTGS2PTGS1 | |
| SCHEMBL5148837 | 0.79 | MTNR1A (0.46) | PTGS2MTNR1AMTNR1BL3MBTL1NPC1 | |
| SCHEMBL5148689 | 0.78 | PTGS2 (0.51) | PTGS2PTGS1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567503-B1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-20070112037-A1 | Pyrazole Derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-7183306-B2 | Pyrazole derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| EP-1567503-A1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050632-A1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112037-A1 | Pyrazole Derivatives | CYP11B2, CYP11B1, CYP3A43 | PTGS2 1780/4885PTGS1 1105/4885MTNR1A 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.